New Kinase Inhibitors That Are Selectively Cytotoxic for Tumor Cells.

D A Skvortsov, I V Zhirkina, D A Ipatova, A R Pisarev, A S Malyshev, Y A Ivanenkov, V G Kartsev, O A Dontsova

Abstract read

In one paragraph

Article in Doklady. Biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

D A SkvortsovChemistry Department and Belozersky Institute of Physico-Chemical Biology, Moscow State University, Moscow, Russia. skvorratd@mail.ru.

I V ZhirkinaChemistry Department and Belozersky Institute of Physico-Chemical Biology, Moscow State University, Moscow, Russia.

D A IpatovaChemistry Department and Belozersky Institute of Physico-Chemical Biology, Moscow State University, Moscow, Russia.

A R PisarevFaculty of Biology and Biotechnologies, Higher School of Economics, Moscow, Russia.

A S MalyshevHertsen Moscow Oncology Research Institute, Moscow, Russia.

Y A IvanenkovHertsen Moscow Oncology Research Institute, Moscow, Russia.

V G KartsevInterBioScreen Ltd, Chernogolovka, Russia.

O A DontsovaChemistry Department and Belozersky Institute of Physico-Chemical Biology, Moscow State University, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To search for substances selectively acting on tumor cells, phenotypic screening in a coculture of tumor cells with non-tumor cells was used in the work. The compound STOCK7S-36520, selectively cytotoxic in the coculture of breast tumor cells MCF7' and non-tumor MCF10A cells, contains structural elements characteristic of kinase inhibitors. Analysis of the compound STOCK7S-36520 and its derivative STOCK7S-47016 showed that they are new multikinase inhibitors. The highest inhibition of 84% was shown by compound STOCK7S-47016 against GCK kinase. Of interest is the significant selectivity of action against some of the cell lines studied: the selectivity index of STOCK7S-36520 against the prostate tumor cell line PC3 is 29 times compared to the model line of non-tumor fibroblasts VA13.

Indexed as

Antineoplastic AgentsProtein Kinase InhibitorsCell Line, TumorHumansMCF-7 CellsPC-3 CellsAntineoplastic AgentsProtein Kinase Inhibitorsanticancer drugscytotoxicityFCCT testkinase inhibitorsselectivity

Identifiers

PMID40216725

DOI10.1134/S1607672924601446

PMCPMC12078342

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.